Introgen Acquires Rights to New Nanotechnology Systems

Targeted Nanoparticles Used to Deliver Proteins, Polypeptides and Peptides

Nov 16, 2006, 00:00 ET from Introgen Therapeutics, Inc.

    AUSTIN, Texas, Nov. 16 /PRNewswire-FirstCall/ -- Introgen Therapeutics,
 Inc. (Nasdaq:   INGN) announced today that it has obtained the exclusive,
 worldwide license to a portfolio of patents from The University of Texas M.
 D. Anderson Cancer Center focused on the delivery of biologically active
 proteins, polypeptides and peptides using novel nanoparticle delivery
 complexes. The technology has demonstrated substantial therapeutic efficacy
 against human lung cancers in animal models. The systemically-delivered
 nanoparticles are applicable to a wide variety of bioactive protein-derived
     The licensed technology is directed to specially designed nanoparticles
 that carry and deliver therapeutic bioactive proteins, polypeptides and
 peptides to targeted cells, such as cancer cells. These nanoparticle
 formulations have certain therapeutic advantages. While peptides alone may
 be rapidly removed from circulation, requiring frequent administration and
 high doses, Introgen's nanoparticle-polypeptide formulations can increase
 therapeutic activity and protect against rapid degradation normally
 associated with peptide therapy. In addition, Introgen's peptide
 nanoparticles can include special targeting molecules to further enhance
 cellular uptake and to improve therapeutic efficacy.
     "Acquiring rights to these nanoparticle delivery technologies
 represents a significant addition to Introgen's drug delivery platforms,"
 said David G. Nance, Introgen's Chief Executive Officer. "While our
 existing programs include nanoparticle delivery of tumor suppressor genes,
 the new technology expands our capabilities to include delivery of
 therapeutic peptides and polypeptides as well as proteins. We expect these
 technologies to enable important advances in the targeted delivery of a
 variety of therapeutic biologics."
     Introgen currently has three therapeutic nanoparticle product
 candidates: INGN 401 (nanoparticle FUS-1), INGN 402 (nanoparticle p53) and
 INGN 403 (nanoparticle mda-7). INGN 401 is currently in phase 1 clinical
 testing for metastatic lung cancer.
     Introgen Therapeutics, Inc. is a biopharmaceutical company focused on
 the discovery, development and commercialization of targeted molecular
 therapies for the treatment of cancer and other diseases. Introgen is
 developing molecular therapeutics, immunotherapies, vaccines and
 nanoparticle therapies to treat a wide range of cancers using tumor
 suppressors and cytokines. Introgen maintains integrated research,
 development, manufacturing, clinical and regulatory departments and
 operates multiple manufacturing facilities including a commercial scale
 cGMP manufacturing facility.
     Introgen holds license agreements with M. D. Anderson Cancer Center to
 commercialize products based on licensed technologies, and has the option
 to license future technologies under sponsored research agreements. The
 University of Texas Board of Regents owns stock in Introgen. These
 arrangements are managed in accordance with M. D. Anderson's conflict of
 interest policies.
     Statements in this release that are not strictly historical may be
 "forward-looking" statements, including those relating to Introgen's future
 success with its nanoparticle delivery systems and clinical programs for
 the treatment of cancer or other diseases. The actual results may differ
 from those described in this release due to risks and uncertainties that
 exist in Introgen's operations and business environment, including
 Introgen's stage of product development and the limited experience in the
 development of protein- based drugs in general, dependence upon proprietary
 technology and the current competitive environment, history of operating
 losses and accumulated deficits, reliance on collaborative relationships,
 and uncertainties related to clinical trials, the safety and efficacy of
 Introgen's product candidates, the ability to obtain the appropriate
 regulatory approvals, Introgen's patent protection and market acceptance,
 as well as other risks detailed from time to time in Introgen's filings
 with the Securities and Exchange Commission, including its filings on Form
 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release
 the results of any revisions to any forward-looking statements that reflect
 events or circumstances arising after the date hereof.
     Editor's Note: For more information on Introgen Therapeutics, or for a
 menu of archived press releases, please visit Introgen's Website at:
     Contact:  Introgen Therapeutics, Inc.
               C. Channing Burke
               (512)708 9310 Ext. 322

SOURCE Introgen Therapeutics, Inc.